Dementia, Mild: Clinical Trials

2 trials for Dementia, Mild, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 enrolling by invitation. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Enrolling by invitation 1
Phase 31Active not recruiting 1

Follow Dementia, Mild: new trials by email Literature Review of Dementia, Mild trials Research Report on Dementia, Mild

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tau PET Outcomes With Anti-amyloid Immunotherapies
18F-AV-1451, C-11 ER-176 - Cognitive Impairment, Mild, Dementia, Mild
Phase 2Enrolling by invitationMayo Clinic1352025-11-042026-10-30
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem, Placebo - Dementia Moderate, Dementia, Mild
Phase 2 / Phase 3Active not recruitingActinogen Medical2472024-04-122026-10-21

Narrower conditions

Alzheimer Disease (2)  ·  Dementia (2)  ·  Lymphoma, Follicular (2)  ·  Cognitive Dysfunction (1)

Broader conditions

Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoproliferative Disorders (2)  ·  Mental Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Nervous System Diseases (2)  ·  Neurocognitive Disorders (2)  ·  Neurodegenerative Diseases (2)

Interventions

7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1)  ·  UE2343 (1)

Sponsors

Actinogen Medical (1)  ·  Mayo Clinic (1)

Countries

United States (2)  ·  Australia (1)

Top investigators

Petrice Cogswell, M.D., Ph.D. (1)